| Literature DB >> 31344670 |
Lise L Kemmeren1,2, Anneke van Schaik1,2, Johannes H Smit1,2, Jeroen Ruwaard1,2, Artur Rocha3, Mário Henriques3, David Daniel Ebert4, Ingrid Titzler4, Jean-Baptiste Hazo5,6,7, Maya Dorsey5,6,7, Katarzyna Zukowska8, Heleen Riper1,2,9.
Abstract
BACKGROUND: Blended treatments, combining digital components with face-to-face (FTF) therapy, are starting to find their way into mental health care. Knowledge on how blended treatments should be set up is, however, still limited. To further explore and optimize blended treatment protocols, it is important to obtain a full picture of what actually happens during treatments when applied in routine mental health care.Entities:
Keywords: cognitive behavior therapy; combined modality therapy; depression; internet; logfile analysis; routine mental healthcare; treatment compliance
Year: 2019 PMID: 31344670 PMCID: PMC6686640 DOI: 10.2196/12707
Source DB: PubMed Journal: JMIR Ment Health ISSN: 2368-7959
Figure 1The 4 blended elements presented over time: blended cognitive behavioral therapy always starts with a 'face-to-face' session. Patients work on the Moodbuster 'Web-based modules' in between the face-to-face sessions and receive 'Web-based feedback' from their therapist through a written message on Moodbuster. During the entire treatment period, patients track their mood daily on the mobile application ('Ecological momentary assessment’).
Scheduled blended treatment format per country in the E-COMPARED (European Comparative Effectiveness Research on Internet-Based Depression Treatment) trial.
| Country | Type of care | Treatment duration (weeks) | Face-to-face/Web-based ratioa |
| Germany | Primary | 11-13 | 6/10 |
| Poland | Primary | 7-10 | 7/6 |
| The Netherlands | Secondary | 18-20 | 10/9 |
| France | Secondary | 16-20 | 8/8 |
aFace-to-face/Web-based ratio represents the total number of recommended face-to-face and Web-based sessions.
Figure 2Moodbuster module flowchart of the blended treatment protocol in E-COMPARED (European Comparative Effectiveness Research on Internet-Based Depression Treatment).
Moodbuster usage metrics, as extracted from raw logfile data.
| Usage metrics | Description | |
| Na of usage weeks | Total number of weeks that Moodbuster has been used by the patient, based on the first and the last login date | |
| N of logins | Total number of times that the patient logged on to the Moodbuster website | |
| N of modules started | Total number of modules where the patient reached at least page 3 (confirming having started the module) | |
| N of modules completed | Total number of modules where the patient visited all pages and filled in the end-of-module questionnaire | |
| Average login duration | Average number of minutes spent on the Moodbuster website per login | |
| Total usage duration | Total minutes spent on the Moodbuster website | |
| N of messages | Total number of messages sent by the therapist or patient | |
| Message length | Average number of characters used per message from the therapist or patient | |
| N of contact weeks | Total number of weeks between the first and the last Web-based message from the therapist or patient | |
| N of mood registrations | Total number of times that patient registered mood state on the Moodbuster mobile app | |
aN: total number.
Figure 3Flowchart of participants. Started blended cognitive behavioral therapy means at least 1 face-to-face session and at least 1 login on the Moodbuster platform. E-COMPARED: European Comparative Effectiveness Research on Internet-Based Depression Treatment. bCBT: blended cognitive behavioral therapy.
Baseline patient characteristics (N=200).
| Patient characteristics | Total | Primary care | Specialized care | ||||
| DEa (n=83) | PLb (n=34) | NLc (n=44) | FRd (n=39) | ||||
| Gender (female), n (%) | 129 (64.5) | 51 (61.4) | 25 (73.5) | 27 (61.4) | 26 (66.7) | .61 | |
| Age (years), mean (SD) | 41.7 (12.9) | 43.2 (13.1) | 36.4 (13.1) | 39.4 (9.8) | 45.9 (13.6) | .005 | |
| Low | 24 (12.0) | 15 (18.1) | 2 (5.9) | 6 (13.6) | 1 (2.6) | .004 | |
| Middle | 74 (37.0) | 21 (25.3) | 11 (32.4) | 24 (54.5) | 18 (46.2) | .004 | |
| High | 102 (51.0) | 47 (56.6) | 21 (61.8) | 14 (31.8) | 20 (51.3) | .004 | |
| In a relationship, n (%) | 117 (58.5) | 51 (61.4) | 24 (70.6) | 24 (54.5) | 18 (46.2) | .17 | |
| Baseline PHQe, mean (SD) | 16.2 (4.7) | 15.5 (4.1) | 16.3 (5.0) | 16.9 (5.8) | 16.8 (4.6) | .33 | |
| Comorbidity, n (%)f | 113 (60.1) | 34 (41.5) | 17 (50.0.9) | 34 (77.3) | 28 (71.8) | <.001 | |
| Blended | 117 (58.5) | 64 (77.1) | 24 (70.6) | 21 (47.7) | 8 (20.5) | <.001 | |
| TAUg | 29 (14.5) | 6 (7.2) | 1 (3.3) | 7 (15.9) | 15 (38.5) | <.001 | |
| Nonh | 54 (27.0) | 13 (15.7) | 9 (26.5) | 16 (36.4) | 16 (41.0) | <.001 | |
aDE: Germany.
bPL: Poland.
cNL: the Netherlands.
dFR: France.
ePHQ: Patient Health Questionnaire-9.
f≥1 comorbid disorder, as assessed with the Mini International Neuropsychiatric Interview.
gTAU: treatment-as-usual.
hNon: no treatment preference.
Usage of blended treatment elements per country.
| Blended treatment elements | Primary care | Specialized care | ||||
| DEa (n=83) | PLb (n=34) | NLc (n=44) | FRd (n=39) | |||
| Mean (SD) | 4.9 (0.6) | 6.7 (3.5) | 7.5 (5.0) | 7.4 (2.3) | ||
| Range | 2-5 | 1-18 | 2-32 | 2-9 | ||
| Mean (SD) | 275 (42) | 342 (182) | 346 (230) | 427 (146) | ||
| Range | 105-387 | 60-925 | 90-1440 | 100-595 | ||
| Mean (SD) | 54.9 (8.3) | 52.0 (7.3) | 46.2 (5.8) | 56.8 (6.7) | ||
| Range | 21-77 | 30-70 | 33-64 | 31-67 | ||
| Mean (SD) | 9.4 (3.2) | 9.5 (6.5) | 16.5 (11.2) | 15.8 (6.1) | ||
| Range | 2-26.1 | 0-30.3 | 2-61 | 2-28 | ||
| Mean (SD) | 12.6 (3.8) | 10.6 (5.6) | 13.2 (7.0) | 13.9 (6.5) | ||
| Range | 2.2-24.8 | 0.7-25.3 | 1.9-25.9 | 0-26.5 | ||
| Mean (SD) | 16.7 (7.1) | 15.8 (7.9) | 11.9 (9.2) | 15.5 (13.9) | ||
| Range | 4-34 | 2-39 | 3-40 | 1-66 | ||
| Mean (SD) | 6.6 (1.0) | 6.1 (1.3) | 4.5 (1.5) | 5.0 (2.0) | ||
| Range | 3-7 | 3-7 | 2-7 | 1-7 | ||
| Mean (SD) | 6.4 (1.3) | 5.6 (1.7) | 3.8 (1.6) | 4.4 (2.1) | ||
| Range | 2-7 | 2-7 | 2-7 | 1-7 | ||
| Mean (SD) | 368 (193) | 396 (246) | 228 (193) | 332 (333) | ||
| Range | 86-1199 | 54-1087 | 53-876 | 22-1455 | ||
| Mean (SD) | 15.3 (5.9) | 6.0 (3.2) | 5.8 (3.9) | 4.3 (3.7) | ||
| Range | 4-39 | 0-13 | 0-14 | 0-12 | ||
| Mean (SD) | 8.3 (5.5) | 3.8 (2.4) | 4.6 (4.0) | 3.1 (2.9) | ||
| Range | 2-32 | 0-11 | 0-17 | 0-12 | ||
| Mean (SD) | 1282 (353) | 471 (284) | 741 (372) | 432 (148) | ||
| Range | 613-2316 | 140-1026 | 133-1636 | 120-702 | ||
| Mean (SD) | 450 (420) | 421 (373) | 533 (350) | 293 (125) | ||
| Range | 137-3874 | 115-1475 | 132-1522 | 94-529 | ||
| Mean (SD) | 11.9 (3.6) | 7.3 (4.7) | 9.7 (7.2) | 8.1 (6.0) | ||
| Range | 1-23.9 | 0-18.1 | 0-24.9 | 0-18 | ||
| Mean (SD) | 14 (5.8) | 12.3 (7.9) | 14.7 (8.5) | 14 (6.5) | ||
| Range | 2.9-25.9 | 0-25.8 | 0-25.7 | 0-25.5 | ||
| Mean (SD) | 128.2 (92) | 58 (42.8) | 71.5 (72.8) | 68.1 (38.5) | ||
| Range | 16-442 | 3-204 | 1-352 | 1-158 | ||
aDE: Germany.
bPL: Poland.
cNL: the Netherlands.
dFR: France.
Engagement groups with blended cognitive behavioral therapy per country.
| Engagement groups | DEa (n=83), n (%) | PLb (n=34), n (%) | NLc (n=44), n (%) | FRd (n=39), n (%) |
| Early dropout | 0 (0) | 0 (0) | 2 (4) | 1 (2) |
| Mainly Web-based | 3 (3) | 4 (11) | 0 (0) | 1 (2) |
| Mainly face-to-face | 0 (0) | 1 (2) | 3 (6) | 6 (15) |
| Blended compliant | 80 (96) | 29 (85) | 39 (88) | 31 (79) |
aDE: Germany.
bPL: Poland.
cNL: the Netherlands.
dFR: France.
Patient characteristics and differences between blended compliant and blended noncompliant groups.
| Patient characteristics | Blended compliant (n=179) | Blended noncompliant (n=52) | Chi-square value (df) | |||
| Gender (female), n (%) | 115 (64.2) | 31 (59.6) | 0.4 (1) | —a | .54 | |
| Age (years), mean (SD) | 41.8 (12.5) | 42.6 (14.2) | — | 0.39 (229) | .69 | |
| Low | 18 (10.1) | 10 (19.2) | 6.1 (2) | — | .048 | |
| Middle | 64 (35.8) | 23 (44.2) | 6.1 (2) | — | ||
| High | 97 (54.2) | 19 (36.5) | 6.1 (2) | — | ||
| In a relationship, n (%) | 109 (60.9) | 24 (46.2) | 3.6 (1) | — | — | |
| Baseline PHQ-9b, mean (SD) | 16.1 (4.9) | 16.1 (6) | — | −0.06 (69) | .95 | |
| Number of comorbid disordersc, mean (SD) | 0.9 (1.1) | 1.3 (1.3) | — | 2.11 (229) | .03 | |
| Blended | 107 (59.8) | 22 (42.3) | 13.1 (2) | — | .001 | |
| TAUd | 21 (11.7) | 17 (32.7) | 13.1 (2) | — | .001 | |
| None | 51 (28.5) | 13 (25) | 13.1 (2) | — | .001 | |
aNot applicable.
bPHQ-9: Patient Health Questionnaire-9.
cAssessed with the Mini International Neuropsychiatric Interview.
dTAU: treatment-as-usual.
eNon: no treatment preference.